Therefore, DOCK2 is considered to be a viable drug target for leukemia, where DOCK2 is overexpressed in chronic lymphocytic leukemia (Wu et al., 2017; Hasan et al., 2018). This evidence concerns the gene DOCK2 and B-cell chronic lymphocytic leukemia.